Quantum BioPharma (NASDAQ: QNTM) has entered into a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to implement a Phase 2 clinical trial of Lucid-21-302 (Lucid-MS) for multiple sclerosis. The agreement initiates formal study start-up activities following FDA clearance to proceed with the trial, as reported by NEWMEDIAWIRE. Thermo Fisher will support study start-up and related clinical research services through its PPD Clinical Research Business.
The randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with progressive forms of MS using clinical and radiological endpoints. Lucid-MS is an investigational, first-in-class new chemical entity designed to provide neuroprotection by inhibiting demyelination through targeting protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. If successful, this approach could represent a novel mechanism for treating progressive MS, a form of the disease with limited therapeutic options. For more details, see the full press release at https://ibn.fm/CZH9U.
The agreement with Thermo Fisher, a global leader in clinical research services, is significant because it leverages established infrastructure and expertise to expedite trial initiation. This partnership could help Quantum BioPharma navigate the complex regulatory and operational challenges of a Phase 2 trial, potentially bringing Lucid-MS closer to market. The trial's progression is critical for a company focused on neurodegenerative disorders, as it validates its scientific approach and could attract further investment or partnerships.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company also invented UNBUZZD and retains a 19.84% ownership in Unbuzzd Wellness Inc. (as of March 31, 2026), with royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity.
Investors and stakeholders can find the latest news and updates relating to QNTM in the company's newsroom at https://ibn.fm/QNTM. The trial's start-up phase is a key milestone that could de-risk the development program and provide valuable data on Lucid-MS's potential to address the unmet needs of progressive MS patients. With no cure currently available for MS, therapies that target underlying mechanisms like demyelination are urgently needed. Quantum BioPharma's progress will be closely watched by the biotech community, as positive results could lead to a major breakthrough in MS treatment.
As with any clinical trial, risks and uncertainties remain, including factors beyond management's control. The company's forward-looking statements are subject to risks detailed in its SEC filings. Nevertheless, the start-up agreement represents a concrete step forward in advancing Lucid-MS and reinforces Quantum BioPharma's commitment to developing innovative therapies for serious neurological conditions.
